Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
Diabetologia
|
April 23, 2013
Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial
B Charbonnel, H Steinberg, E Eymard, et al.
Diabetes, Obesity & Metabolism
|
January 21, 2015
Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
M A Bethel, J B Green, J Milton, et al.
International Journal of Clinical Practice
|
April 12, 2013
Recent trends in the characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large U.S. claims database
K G Brodovicz, T D Kou, C M Alexander, et al.
International Journal of Clinical Practice
|
February 6, 2015
A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus
R R Shankar, L Xu, G T Golm, et al.
Diabetes, Obesity & Metabolism
|
July 27, 2012
Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk
K G Brodovicz, T D Kou, C M Alexander, et al.
International Journal of Clinical Practice
|
April 24, 2010
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
S S Engel, D E Williams-Herman, G T Golm, et al.
Diabetes, Obesity & Metabolism
|
November 9, 2011
Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes
J Wainstein, L Katz, S S Engel, et al.
International Journal of Clinical Practice
|
August 19, 2011
Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes
A Pérez-Monteverde, T Seck, L Xu, et al.
Current Medical Research and Opinion
|
April 9, 2015
Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes
H L Katzeff, D Williams-Herman, L Xu, et al.
Diabetes, Obesity & Metabolism
|
January 23, 2010
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
T Vilsbøll, J Rosenstock, H Yki-Järvinen, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
Diabetologia
|
April 23, 2013
Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial
B Charbonnel, H Steinberg, E Eymard, et al.
Diabetes, Obesity & Metabolism
|
January 21, 2015
Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
M A Bethel, J B Green, J Milton, et al.
International Journal of Clinical Practice
|
April 12, 2013
Recent trends in the characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large U.S. claims database
K G Brodovicz, T D Kou, C M Alexander, et al.
International Journal of Clinical Practice
|
February 6, 2015
A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus
R R Shankar, L Xu, G T Golm, et al.
Diabetes, Obesity & Metabolism
|
July 27, 2012
Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk
K G Brodovicz, T D Kou, C M Alexander, et al.
International Journal of Clinical Practice
|
April 24, 2010
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
S S Engel, D E Williams-Herman, G T Golm, et al.
Diabetes, Obesity & Metabolism
|
November 9, 2011
Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes
J Wainstein, L Katz, S S Engel, et al.
International Journal of Clinical Practice
|
August 19, 2011
Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes
A Pérez-Monteverde, T Seck, L Xu, et al.
Current Medical Research and Opinion
|
April 9, 2015
Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes
H L Katzeff, D Williams-Herman, L Xu, et al.
Diabetes, Obesity & Metabolism
|
January 23, 2010
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
T Vilsbøll, J Rosenstock, H Yki-Järvinen, et al.
Page
of 3